Overview

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Status:
Completed

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Collaborator:

JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Treatments:

QS 21